Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

Abstract Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated with poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present BMF data from Janus kinase (JAK) inhibitor–naive patients from SIMPLIFY‐1 (NCT01969838...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stephen T. Oh, Srdan Verstovsek, Vikas Gupta, Uwe Platzbecker, Timothy Devos, Jean‐Jacques Kiladjian, Donal P. McLornan, Andrew Perkins, Maria Laura Fox, Mary Frances McMullin, Adam J. Mead, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben Mesa
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-02-01
Col·lecció:	eJHaem
Matèries:	bone marrow fibrosis JAK inhibitor momelotinib myelofibrosis ruxolitinib
Accés en línia:	https://doi.org/10.1002/jha2.854
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!